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The vascular network is a highly accessible target for tumor therapy. However, as for any 
cancer treatment, the primary goal is to deliver sufficient amounts of drug to the targeted 
tissue while minimizing damage to healthy organs. Cationic liposomes have been identified as 
delivery systems significantly more effective at targeting tumor versus normal vascular 
networks. Though, the liposome uptake by the liver restricts their potential as shuttles to 
selectively target the tumor endothelium. Here, we reasoned that additional selectivity could 
be found in the nature of the delivered gene and by combining another anti-tumor therapy. 
Accordingly, the pro-survival PI3K /Akt pathway is thought to be activated by ionizing 
radiations and a dominant-negative Akt would therefore mostly target tumors (versus non-
irradiated organs). Furthermore, we have recently documented that irradiation led to NO-
mediated tumor vessel dilation which could thereby enhance the access of liposomes to the 
tumor. In this study, we have therefore examined whether radiotherapy and the use of 
dominant-negative Akt plasmid delivered by cationic liposomes could mutually improve their 
efficacies. We first used cultured endothelial cells and isolated tumor microvessels to 
demonstrate that low dose irradiation led to the stimulation of both Ser473 Akt and Ser1177 
eNOS phosphorylations (e.g., activation); the use of a PI3K inhibitor further indicated that the 
former largely accounted for the increased NO/cGMP production. Using a reporter-encoding 
plasmid, we then showed that irradiation dramatically enhanced the in vivo expression of the 
tagged protein in the tumor endothelium. Also, using eNOS–/– mice, we documented the key 
role of NO in mediating the adjuvant effects of X-Ray on plasmid delivery, likely through an 
increase in tumor blood flow. We then combined local irradiation to the liposome-dominant 
negative Akt DNA complex administration. In two different protocols associating gene 
therapy with either a single 6 Gy dose or a 5 x 2 Gy fractionated scheme, we consistently 
observed synergistic effects of the combinatory treatment. In fact, the transgene when 
administered alone, did not reveal any tumor response and the tumor growth delay after 
irradiation represented less than 50% of the gain obtained when combining both approaches 
(n=8; P<0.01); these findings were obtained in two mouse tumor models. In conclusion, the 
combination of low dose radiotherapy and liposome-cargoed dominant-negative Akt gene 
therapy appears particularly well suited to selectively target tumor vasculature. Besides the 
intrinsic tumor specificity of local X-Ray administration and the propensity of cationic 
liposomes to bind tumor vessels, we have further identified a "treatment-driven" selectivity, 
e.g. the ability of radiotherapy to induce Akt activation in tumor vasculature and to increase 
the liposome access to the tumor.  
 
